Phreesia Dirección
Dirección controles de criterios 3/4
El CEO de Phreesia es Chaim Indig , nombrado en Jan 2005, tiene una permanencia de 21.5 años. compensación anual total es $8.26M, compuesta por 6.2% salario y 93.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 2.32% de las acciones de la empresa, por valor de $15.81M. La antigüedad media del equipo directivo y de la junta directiva es de 3.3 años y 7.2 años, respectivamente.
Información clave
Chaim Indig
Chief Executive Officer (CEO)
US$8.3m
Compensación total
| Porcentaje del salario del CEO | 6.23% |
| Permanencia del CEO | 21.5yrs |
| Participación del CEO | 2.3% |
| Permanencia media de la dirección | 3.3yrs |
| Promedio de permanencia en la Junta Directiva | 7.2yrs |
Actualizaciones recientes de la dirección
Recent updates
Actualización de narrativa • Jul 01
PHR: Cost Discipline And Profit Focus Will Drive Long Term Upside
Phreesia's analyst fair value estimate has been reduced from $35.00 to $20.00, reflecting lower assumed revenue growth and profit margins as analysts weigh slower digital advertising trends, rising competitive pressure, and less visibility into a return to durable organic growth. Analyst Commentary Recent Street research on Phreesia highlights a more cautious tone, with several firms cutting ratings and trimming price targets as they reassess growth visibility, digital advertising trends, and competitive pressure.
Actualización de narrativa • Jun 17
PHR: Cost Discipline And Profit Focus Will Support Stock Multiple Recovery
Analysts have trimmed their average price target on Phreesia stock by a few dollars into the low teens. This reflects concern that cost cutting is coming alongside reduced visibility on organic growth and rising competitive pressure in digital health advertising.Seeking Alpha • Jun 15
Phreesia: Rating Downgrade As Growth Outlook Worsens
Summary Phreesia is downgraded to Hold as profitability improves, but growth outlook becomes less compelling. PHR's EBITDA and free cash flow are rising, but revenue growth is slowing and increasingly reliant on acquired payments. Subscription revenue is declining, and organic payment solutions growth remains weak despite the AccessOne acquisition. Valuation is historically low; upside depends on evidence of organic growth and successful cross-selling of AccessOne. Read the full article on Seeking AlphaArtículo de análisis • Jun 10
Phreesia's (NYSE:PHR) Performance Is Even Better Than Its Earnings Suggest
Phreesia, Inc.'s ( NYSE:PHR ) strong earnings report was rewarded with a positive stock price move. Our analysis found...Actualización de narrativa • Jun 01
PHR: Cost Discipline And Higher Margins Will Support Multiple Recovery
Analysts have reduced their average price target for Phreesia by about $1, to roughly $14. Lower revenue growth expectations and multiple downgrades related to growth visibility and competitive pressures are only partly offset by improving profit margin assumptions and a lower projected P/E.Actualización de narrativa • May 17
PHR: Post Reset Execution On Profitability And Intake Reach Will Support Multiple
Analysts have trimmed their fair value estimate for Phreesia from about $16.17 to $15.39 and lowered the future P/E assumption, reflecting a broad reset in price targets as firms point to slowing digital advertising growth and rising competition. Analyst Commentary Recent research points to a sharp reset in expectations for Phreesia, with multiple firms cutting price targets and, in several cases, downgrading ratings.Actualización de narrativa • Apr 24
PHR: Post Guidance Reset Execution On Profitability And Intake Reach Will Support Multiple
The updated analyst price target for Phreesia reflects a modest downward adjustment of around $0.28, with analysts pointing to slightly lower assumptions for revenue growth, profit margin, and future P/E, along with a small change in the discount rate. Analyst Commentary Recent research updates on Phreesia have been concentrated on lowering price targets and, in several cases, revising ratings, which points to a clear reset in expectations around growth, profitability, and execution risk.Actualización de narrativa • Apr 10
PHR: Profitability Focus And Intake Reach Will Support Post Guidance Reset Multiple Resilience
Analysts have reduced their average price target on Phreesia to reflect a lower fair value estimate of about $16.44, down from roughly $27.89. They cited more conservative assumptions for revenue growth, profit margins and future P/E multiples after a broad wave of target cuts and downgrades from multiple firms.Actualización de narrativa • Mar 26
PHR: Profitability Focus And Intake Reach Will Support Future Multiple Resilience
Analyst price targets on Phreesia have been trimmed by a few dollars to around the mid $20s, as analysts factor in slightly lower revenue growth and profit margin assumptions while still using a relatively high future P/E of about 37x. Analyst Commentary Recent Street research on Phreesia has centered on fine tuning price targets and reassessing how much investors should pay for the company’s earnings profile, rather than making wholesale shifts in views on the business itself.Actualización de narrativa • Mar 11
PHR: Profitability Pivot And Intake Network Breadth Will Support Future Margin Expansion
Analysts have trimmed their average price targets on Phreesia by roughly $5 to the mid $20s, reflecting a mix of caution after a challenging period for health tech stocks and continued confidence in the company’s profitability pivot and patient intake platform. Analyst Commentary Recent Street research on Phreesia clusters around a common theme, lower price targets but generally constructive views on the company’s execution and path to profitability.Actualización de narrativa • Feb 24
PHR: Profitability Pivot And AccessOne Integration Will Drive Future Margin Expansion
The updated analyst price target for Phreesia reflects a modest trim of fair value to about $28.05, as analysts recalibrate their models following a series of target cuts to the $24 to $30 range. They continue to cite the company’s profitability pivot and patient intake platform scale as key parts of the long-term thesis.Actualización de narrativa • Feb 10
PHR: Profitability Pivot And AccessOne Integration Will Support Future Margin Expansion
Analysts have nudged their price targets on Phreesia slightly lower, trimming fair value estimates by about $0.32 to reflect modestly updated assumptions on discount rates, margins, and future P/E. At the same time, recent research highlights both reduced targets in health tech and continued optimism around the company’s patient intake and payments platform.Actualización de narrativa • Jan 26
PHR: Profitability Pivot And AccessOne Synergies Will Support Future EBITDA Improvement
Analysts have nudged their fair value estimate for Phreesia slightly lower to about $28.63 per share, reflecting modestly softer assumptions for revenue growth, profit margins, and future P/E multiples following a series of recent price target cuts and fresh coverage initiations. Analyst Commentary Recent research paints a mixed picture for Phreesia, with several firms trimming price targets while others initiate or resume positive ratings.Actualización de narrativa • Jan 12
PHR: Profitability Pivot And AccessOne Integration Will Support Future Margin Expansion
Analysts trimmed their fair value estimate for Phreesia to about $29.16 from $29.82 and lowered future P/E assumptions, pointing to reduced Street price targets in the mid $20s, even as research notes highlight the company’s profitability focus, margin progress, and reach across U.S. patient visits. Analyst Commentary Street research on Phreesia is mixed, with several firms trimming price targets while still highlighting profitability efforts, margin progress, and the scale of the platform across U.S. patient visits.Actualización de narrativa • Dec 24
PHR: Cross Sell And AccessOne Integration Will Drive Future EBITDA Expansion
Narrative Update Analysts have modestly trimmed their price target on Phreesia to approximately $29.82 from about $32.12 per share, reflecting slightly lower assumptions for revenue growth and profit margins even as they highlight the company’s growing cross-sell traction, long-term lift from the pending AccessOne acquisition, and potential for significant operating leverage to drive EBITDA growth in the high-20s to low-30s percentage range. Analyst Commentary Analysts generally view Phreesia positively, with recent coverage initiating the stock with an Outperform rating and a price target modestly above current levels, citing a strengthening growth and profitability profile.Actualización de narrativa • Dec 10
PHR: Cross Selling Momentum Will Drive Stronger Long Term EBITDA Expansion
Analysts have modestly reduced their price target on Phreesia from $33.73 to $32.12 per share, citing expectations for stronger long term EBITDA growth supported by cross selling traction and operating leverage, as well as incremental upside from the pending AccessOne acquisition. Analyst Commentary Analysts highlight that Phreesia's current valuation reflects confidence in its ability to execute on growth initiatives while expanding margins, but they also caution that the shares already price in a meaningful portion of the long term opportunity.Artículo de análisis • Sep 27
Phreesia, Inc.'s (NYSE:PHR) 26% Cheaper Price Remains In Tune With Revenues
Phreesia, Inc. ( NYSE:PHR ) shareholders won't be pleased to see that the share price has had a very rough month...Actualización de narrativa • Sep 06
AI Integration And Digital Adoption Will Expand Healthcare Services
Phreesia’s price target increased to $33.73 as analysts responded positively to solid Q2 results, upwardly revised FY26 EBITDA guidance, strategic product launches, and the AccessOne acquisition—despite valuation concerns—supporting a strong double-digit growth outlook and margin expansion. Analyst Commentary Solid Q2 results, with revenues in line and adjusted EBITDA ahead of consensus; company raised FY26 EBITDA guidance driven by effective expense management.Nueva narrativa • May 27
Digital Healthcare Tools Will Expand Market Reach
Expanding digital adoption and data-driven solutions are driving operational efficiency, deeper client relationships, and long-term recurring revenue growth.Artículo de análisis • Apr 29
Revenues Tell The Story For Phreesia, Inc. (NYSE:PHR)
There wouldn't be many who think Phreesia, Inc.'s ( NYSE:PHR ) price-to-sales (or "P/S") ratio of 3.4x is worth a...Artículo de análisis • Mar 07
Why Phreesia, Inc. (NYSE:PHR) Could Be Worth Watching
Phreesia, Inc. ( NYSE:PHR ), might not be a large cap stock, but it saw a double-digit share price rise of over 10% in...Artículo de análisis • Feb 14
Phreesia (NYSE:PHR) Has Debt But No Earnings; Should You Worry?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Artículo de análisis • Dec 27
Phreesia, Inc.'s (NYSE:PHR) Shares Climb 27% But Its Business Is Yet to Catch Up
Phreesia, Inc. ( NYSE:PHR ) shareholders would be excited to see that the share price has had a great month, posting a...Seeking Alpha • Dec 12
Phreesia Has Turned The Corner, Can It Continue To Mend?
Summary Phreesia’s Q3 earnings show solid revenue growth, but customer growth is decelerating, impacting overall performance. Fiscal 2025 guidance improved with higher EBITDA and tighter revenue estimates, while fiscal 2026 projects slower revenue growth but significant EBITDA improvement. Strong cash flow and disciplined expense management are encouraging, with the company maintaining positive cash flows and holding $82M in cash. Despite current trading challenges, Phreesia’s innovative healthcare solutions and partnerships position it well for future growth and potential valuation recovery. Read the full article on Seeking AlphaArtículo de análisis • Nov 07
Market Participants Recognise Phreesia, Inc.'s (NYSE:PHR) Revenues
With a price-to-sales (or "P/S") ratio of 3.1x Phreesia, Inc. ( NYSE:PHR ) may be sending bearish signals at the...Artículo de análisis • Oct 08
Is Phreesia (NYSE:PHR) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Artículo de análisis • Sep 06
Here's What Analysts Are Forecasting For Phreesia, Inc. (NYSE:PHR) After Its Second-Quarter Results
Phreesia, Inc. ( NYSE:PHR ) last week reported its latest second-quarter results, which makes it a good time for...Seeking Alpha • Sep 05
Phreesia: Remain Bullish Given The Healthy Growth Outlook
Summary I maintain a buy rating for PHR, driven by strong client growth, solid revenue outlook, and increasing transaction sizes in the pipeline. PHR's 2Q25 results show 19% y/y revenue growth and improved profitability, with positive EBITDA and FCF, indicating strong financial health. Despite a slight decline in revenue per AHSC, larger client acquisitions and increased transaction sizes support my 20% growth expectation. Read the full article on Seeking AlphaArtículo de análisis • Jul 18
Market Participants Recognise Phreesia, Inc.'s (NYSE:PHR) Revenues Pushing Shares 26% Higher
Phreesia, Inc. ( NYSE:PHR ) shareholders would be excited to see that the share price has had a great month, posting a...Seeking Alpha • Jun 06
Phreesia: Growth Remains Strong, With EBITDA Margin Set To Improve
Summary Phreesia's revenue grew 20.7% year-over-year, with subscription revenue growing 23.4% and payment processing revenue growing 11.6%. The company added 103 new clients in the quarter, beating guidance, and expects to add around 100 more in the next quarter. Phreesia's focus on profitability is showing positive results, with EBITDA margin expanding and guidance suggesting further improvement. Read the full article on Seeking AlphaAnálisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Apr 30 2026 | n/a | n/a | US$9m |
| Jan 31 2026 | US$8m | US$515k | US$2m |
| Oct 31 2025 | n/a | n/a | -US$5m |
| Jul 31 2025 | n/a | n/a | -US$24m |
| Apr 30 2025 | n/a | n/a | -US$43m |
| Jan 31 2025 | n/a | n/a | -US$59m |
| Oct 31 2024 | n/a | n/a | -US$83m |
| Jul 31 2024 | n/a | n/a | -US$100m |
| Apr 30 2024 | n/a | n/a | -US$119m |
| Jan 31 2024 | US$8m | US$495k | -US$137m |
| Oct 31 2023 | n/a | n/a | -US$144m |
| Jul 31 2023 | n/a | n/a | -US$152m |
| Apr 30 2023 | n/a | n/a | -US$162m |
| Jan 31 2023 | US$8m | US$515k | -US$176m |
| Oct 31 2022 | n/a | n/a | -US$185m |
| Jul 31 2022 | n/a | n/a | -US$181m |
| Apr 30 2022 | n/a | n/a | -US$158m |
| Jan 31 2022 | US$9m | US$515k | -US$118m |
| Oct 31 2021 | n/a | n/a | -US$80m |
| Jul 31 2021 | n/a | n/a | -US$50m |
| Apr 30 2021 | n/a | n/a | -US$32m |
| Jan 31 2021 | US$6m | US$419k | -US$27m |
| Oct 31 2020 | n/a | n/a | -US$23m |
| Jul 31 2020 | n/a | n/a | -US$19m |
| Apr 30 2020 | n/a | n/a | -US$83m |
| Jan 31 2020 | US$10m | US$346k | -US$91m |
Compensación vs. Mercado: La compensación total de Chaim($USD8.26M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD3.53M).
Compensación vs. Ingresos: La compensación de Chaim ha sido consistente con los resultados de la empresa en el último año.
CEO
Chaim Indig (47 yo)
21.5yrs
Permanencia
US$8,262,693
Compensación
Mr. Chaim Indig co-founded Phreesia, Inc. in January 2005 and serves as Chief Executive Officer and Director since January 2005. Mr. Indig has helped to revolutionize the patient check-in experience. Under...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 21.5yrs | US$8.26m | 2.32% $ 15.8m | |
| Co-Founder & President of Provider Solutions | 21.5yrs | US$3.66m | 1.14% $ 7.8m | |
| Chief Financial Officer | 3.3yrs | US$3.66m | 0.031% $ 214.6k | |
| General Counsel & Secretary | 5.9yrs | US$2.65m | 0.26% $ 1.7m | |
| President of Network Solutions | 7.3yrs | US$3.63m | 0.15% $ 1.1m | |
| Senior VP & Chief Accounting Officer | less than a year | sin datos | 0.039% $ 263.7k | |
| Chief Technology Officer | 2.3yrs | sin datos | sin datos | |
| Vice President of Marketing | no data | sin datos | sin datos | |
| Senior Vice President of Human Resources | 16.3yrs | sin datos | 0.27% $ 1.9m | |
| Chief Information Security Officer | 1.5yrs | sin datos | sin datos | |
| Senior Vice President of Product | less than a year | sin datos | sin datos | |
| Senior Vice President of Provider Sales | less than a year | sin datos | sin datos |
3.3yrs
Permanencia media
47yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de PHR se considera experimentado (3.3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 21.5yrs | US$8.26m | 2.32% $ 15.8m | |
| Board Observer | no data | sin datos | sin datos | |
| Member of Medical Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 6yrs | US$224.93k | 0.018% $ 124.6k | |
| Independent Director | 7.2yrs | US$247.43k | 0.017% $ 112.7k | |
| Member of Medical Advisory Board | no data | sin datos | sin datos | |
| Member of Medical Advisory Board | no data | sin datos | sin datos | |
| Member of Medical Advisory Board | no data | sin datos | sin datos | |
| Member of Medical Advisory Board | no data | sin datos | sin datos | |
| Member of Medical Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 7.8yrs | US$234.99k | 0.0099% $ 67.4k | |
| Independent Chairman | 4.8yrs | US$234.99k | 0.043% $ 294.9k |
7.2yrs
Permanencia media
55yo
Promedio de edad
Junta con experiencia: La junta directiva de PHR se considera experimentada (7.2 años de antigüedad promedio).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/14 08:05 |
| Precio de las acciones al final del día | 2026/07/14 00:00 |
| Beneficios | 2026/04/30 |
| Ingresos anuales | 2026/01/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Phreesia, Inc. está cubierta por 23 analistas. 18 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Joseph Vruwink | Baird |
| Glen Santangelo | Barclays |
| Zhilin Long | Berenberg |